Sun Pharmaceutical Industries continues enjoying rich valuations on the bourses, thanks to its ability to consistently deliver good growth. The September quarter results were no different. The strong top line growth of 42 per cent came on the back of 16 per cent rise in domestic sales and 77 per cent jump in the US sales that together contributed four-fifths of sales.